Dr. Michael Hoffmann
Dr Michael Hoffmann was named chairman of the Novaliq supervisory board in 2022. Michael is a lawyer and since 2017 a member of the management board of the Hopp Family Office. He serves in various advisory and supervisory boards. He holds a Master degree (LL.M.) from the London School of Economics and a Ph.D. in law from the University of Trier.Dr. Klaus Schollmeier
Mr. Geuder is CEO and managing director of the Geuder Group and Geuder AG in Heidelberg, Germany.
The Geuder AG has been one of the most innovative eye surgical product manufacturers for the past 65 years. Ophthalmic surgeons in over 90 countries rely on more than 3,000 Geuder products when performing surgical operations.
Mr. Geuder is also managing director of the Fluoron® GmbH in Ulm, Germany an affiliate of the Geuder AG. Fluoron GmbH develops and manufactures ultrapure innovative biomaterials for retinal and cataract surgery. Fluoron GmbH plays a leading role in this field worldwide.
Dr. Mathias Hothum
Dr. Hothum is managing director of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech investments of SAP co-founder Dietmar Hopp. He received his degree in Economics from the University of Mannheim and his doctorate from the University of Magdeburg.
For the past 20 years, he has worked as an economist in the sectors of healthcare, health services and life sciences. Mathias specializes in pricing, reimbursement and the evaluation of mid-sized companies, as well as of publicly-owned/market-listed companies. He is the owner and founder of HMM Consulting. Furthermore, he is Chairman of the board of joimax GmbH and board member of CureVac AG, Heidelberg Pharma AG, Apogenix AG, Molecular Health GmbH and Novaliq GmbH.
Dr. Thomas Kaercher, M.D.
Dr. Thomas Kaercher is an independent ophthalmologist in Heidelberg, Germany.
Dr. Kaercher graduated with a medical degree from Heidelberg University and undertook further training at the University of London, UK, before specialising in ophthalmology at Heidelberg University`s ophthalmic hospital. He worked as a senior physician at the ophthalmic hospital of Ludwigshafen, Germany.
Dr. Kaercher`s research interests include dry eye, Meibomian gland diseases, ocular surface diseases, contact lenses and ectodermal dysplasia syndromes. He is a member of the German Ophthalmologic Society, and the Association of German Ophthalmologists. He also works as one of the four members of the German Dry Eye Group. He is active in the scientific board of the German-speaking patient support group for ectodermal dysplasia and is a member of the judging panel for the German Sicca Award.
Dr. Klaus Schollmeier
Klaus Schollmeier is an advisor to the Pharma/Biotech industry and member of the board/chairman of several Biotech companies including Tacalyx (Germany), Modra Pharmaceuticals (Netherlands), Affiris Pharma (Austria), CureVac (Germany) and Eternygen (Germany). He advices and mentors a number of start-up companies in Europe as Entrepreneur in residence and business angel, including BASF’s company builder Chemovator. Dr. Schollmeier was CEO SuppreMol GmbH from 2013 until 2015, when the company was sold to Baxalta. Prior to that, he served as CEO Santhera (Switzerland) from 2004 to 2011 and their chairman of the board until 2013. Prior to joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe having previously spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott.
Dr Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.